title: A review of the ligands and related targeting strategies for active targeting of paclitaxel to tumours.
abstract: It has been 30 years since the discovery of the anti-tumour property of paclitaxel (PTX), which has been successfully applied in clinic for the treatment of carcinomas of the lungs, breast and ovarian. However, PTX is poorly soluble in water and has no targeting and selectivity to tumour tissue. Recent advances in active tumour targeting of PTX delivery vehicles have addressed some of the issues related to lack of solubility in water and non-specific toxicities associated with PTX. These PTX delivery vehicles are designed for active targeting to specific cancer cells by the addition of ligands for recognition by specific receptors/antigens on cancer cells. This article will focus on various ligands and related targeting strategies serving as potential tools for active targeting of PTX to tumour tissues, illustrating their use in different tumour models. This review also highlights the need of further studies on the discovery of receptors in different cells of specific organ and ligands with binding efficiency to these specific receptors.
authors.affiliation: a Department of Pharmacy , The Second Hospital of Shandong University , Jinan , PR China ;
authors.forename: Juan
authors.initials: J
authors.lastname: Li
authors.affiliation: b Key Laboratory of Chemical Biology of Natural Products (Ministry of Education) , Institute of Biochemical and Biotechnological Drugs, School of Pharmaceutical Sciences, Shandong University , Jinan , China ;|c National Glycoengineering Research Center , Shandong University , Jinan , China.
authors.forename: Fengshan
authors.initials: F
authors.lastname: Wang
authors.affiliation: a Department of Pharmacy , The Second Hospital of Shandong University , Jinan , PR China ;
authors.forename: Deqing
authors.initials: D
authors.lastname: Sun
authors.affiliation: a Department of Pharmacy , The Second Hospital of Shandong University , Jinan , PR China ;
authors.forename: Rongmei
authors.initials: R
authors.lastname: Wang
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000627:therapeutic use; D045744:Cell Line, Tumor; D004337:Drug Carriers / Q000737:chemistry* / Q000493:pharmacokinetics; D006801:Humans; D008024:Ligands; D008823:Micelles; D058990:Molecular Targeted Therapy; D053758:Nanoparticles / Q000737:chemistry*; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D017239:Paclitaxel / Q000008:administration & dosage* / Q000627:therapeutic use; D011485:Protein Binding; D011956:Receptors, Cell Surface / Q000378:metabolism
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D008024:Ligands; D008823:Micelles; D011956:Receptors, Cell Surface; D017239:Paclitaxel
keywords: Active tumour targeting; ligands; monoclonal antibodies; paclitaxel; polysaccharide; protein and oligopeptides; small targeting molecules